Sinovac Biotech, Ltd. (AMEX: SVA) is one of the emerging biotech companies in China. Sinovac (also known in China as Beijing Kexing Bioproducts) specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and “SARS”. While the young company has gained national recognition for its Hepatitis A vaccine, they are the only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS. For further information, visit the company website at: www.Sinovac.com.
- 17 years ago
QualityStocks
Sinovac Biotech, Ltd. (AMEX: SVA)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) was awarded an additional $18.4 million funding from the…
-
QualityStocksNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) (FSE: Z7D) CEO Shares Bold Strategy on Exploring Mining Podcast
ESGold (CSE: ESAU) (OTCQB: ESAUF) (FSE: Z7D) was recently featured on the Exploring Mining podcast, where new CEO…
-
QualityStocksNewsBreaks – Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Advances Integrated Approach in Broader Growth Strategy
Nicola Mining (TSX.V: NIM) (OTCQB: HUSIF) recently took a significant step in fostering industry collaboration and…